MX2015016371A - Métodos y composiciones para ensamblaje templado de heterocompuestos específicos de acido nucleico. - Google Patents

Métodos y composiciones para ensamblaje templado de heterocompuestos específicos de acido nucleico.

Info

Publication number
MX2015016371A
MX2015016371A MX2015016371A MX2015016371A MX2015016371A MX 2015016371 A MX2015016371 A MX 2015016371A MX 2015016371 A MX2015016371 A MX 2015016371A MX 2015016371 A MX2015016371 A MX 2015016371A MX 2015016371 A MX2015016371 A MX 2015016371A
Authority
MX
Mexico
Prior art keywords
nucleic acid
moiety
methods
templated assembly
heterocompounds
Prior art date
Application number
MX2015016371A
Other languages
English (en)
Inventor
Dunn Ian
Lawler Matthew
Original Assignee
Tribiotica Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tribiotica Llc filed Critical Tribiotica Llc
Publication of MX2015016371A publication Critical patent/MX2015016371A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025—Nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La presente descripción se dirige a métodos y productos para sintetizar y utilizar reaccionantes de ensamblaje con plantilla que comprenden al menos un resto de reconocimiento de ácido nucleico, al menos un resto de reacción selectiva y al menos un resto parcial efector. El resto de reconocimiento de ácido nucleico puede unirse a una secuencia de ácido nucleico objetivo en una muestra. El resto de reconocimiento de ácido nucleico también puede unirse al resto de reacción selectiva. De forma adicional, el resto parcial efector puede unirse al resto de reacción selectiva para producir una estructura efectora activa. También se describen métodos para suministrar los reaccionantes de ensamblaje con plantilla dirigidos y las estructuras efectoras activas formadas a partir de los reaccionantes de ensamblaje con plantilla dirigidos.
MX2015016371A 2013-06-04 2014-06-04 Métodos y composiciones para ensamblaje templado de heterocompuestos específicos de acido nucleico. MX2015016371A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361831133P 2013-06-04 2013-06-04
PCT/US2014/040822 WO2014197547A1 (en) 2013-06-04 2014-06-04 Methods and compositions for templated assembly of nucleic acid specific heterocompounds

Publications (1)

Publication Number Publication Date
MX2015016371A true MX2015016371A (es) 2017-02-15

Family

ID=52008550

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016371A MX2015016371A (es) 2013-06-04 2014-06-04 Métodos y composiciones para ensamblaje templado de heterocompuestos específicos de acido nucleico.

Country Status (12)

Country Link
US (2) US10603385B2 (es)
EP (1) EP3004351B1 (es)
JP (1) JP6710157B2 (es)
CN (1) CN105358691A (es)
AU (2) AU2014275010B2 (es)
CA (1) CA2950117C (es)
HK (1) HK1222201A1 (es)
IL (1) IL242797B (es)
MX (1) MX2015016371A (es)
SG (2) SG11201509882WA (es)
WO (1) WO2014197547A1 (es)
ZA (1) ZA201600024B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950117C (en) 2013-06-04 2023-02-14 Tribiotica Llc Methods and compositions for templated assembly of nucleic acid specific heterocompounds
CN107208313B (zh) 2014-12-02 2022-01-07 特里比奥迪卡有限责任公司 用于治疗诊断应用的方法和试剂盒
US20230193244A1 (en) * 2016-11-21 2023-06-22 Tribiotica Llc Methods For Split-Protein Template Assembly By Proximity-Enhanced Reactivity
US11186839B2 (en) 2016-11-21 2021-11-30 Tribiotica Llc Methods for preventing titration of bimolecular templated assembly reactions by structurally-determined differential hybridizations
US11253536B2 (en) 2016-11-21 2022-02-22 Tribiotica Llc Methods for directed folding assembly or dimerization of proteins by templated assembly reactions
CN110982876B (zh) * 2020-03-04 2020-05-26 圣湘生物科技股份有限公司 病毒核酸检测的预处理方法、预处理液、试剂盒及其用途
US20230414764A1 (en) * 2020-11-09 2023-12-28 The General Hospital Corporation Template Assembly by Proximity-Enhanced Reactivity via Metabolic Labeling

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020096A1 (en) 1991-05-08 1993-10-14 Stratagene Oligonucleotide libraries useful for producing primers
US5514546A (en) 1993-09-01 1996-05-07 Research Corporation Technologies, Inc. Stem-loop oligonucleotides containing parallel and antiparallel binding domains
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US20020172965A1 (en) 1996-12-13 2002-11-21 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
CA2403209A1 (en) * 1999-04-08 2000-10-19 Pavel V. Sergeev Synthesis of biologically active compounds in cells
US7256259B2 (en) 2000-05-12 2007-08-14 Wisconsin Alumni Research Foundation Methods for ligation of molecules to surfaces
US7297494B2 (en) * 2001-06-25 2007-11-20 Georgia Tech Research Corporation Activatable probes and methods for in vivo gene detection
WO2004011486A2 (fr) * 2002-07-26 2004-02-05 Pierre Fabre Medicament Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une response de type ctl antitumorale ou anti-infectieuse
ES2368215T3 (es) * 2002-10-30 2011-11-15 Nuevolution A/S Codificación enzimática.
US8420086B2 (en) * 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US20050026178A1 (en) 2003-03-28 2005-02-03 Marit Nilsen-Hamilton Allosteric probes and methods
EP1828381B1 (en) 2004-11-22 2009-01-07 Peter Birk Rasmussen Template directed split and mix systhesis of small molecule libraries
CN100381460C (zh) 2004-11-30 2008-04-16 北京市肿瘤防治研究所 Her-2模拟抗原表位及含有该表位的肽
US20060147963A1 (en) * 2004-12-30 2006-07-06 Affymetrix, Inc. Detection of polynucleotides on nucleic acid arrays using azido-modified triphosphate nucleotide analogs
US7795009B2 (en) * 2005-06-15 2010-09-14 Saint Louis University Three-component biosensors for detecting macromolecules and other analytes
EP3591069A3 (en) * 2005-10-27 2020-03-04 The President and Fellows of Harvard College Methods and compositions for labeling nucleic acids
WO2008029281A2 (en) 2006-02-10 2008-03-13 Invitrogen Corporation Labeling and detection of post translationally modified proteins
US8114636B2 (en) 2006-02-10 2012-02-14 Life Technologies Corporation Labeling and detection of nucleic acids
JP2009534342A (ja) 2006-04-20 2009-09-24 サイレンス・セラピューティクス・アーゲー 血管内皮に特異的に送達するためのリポプレックス処方剤
JP2009535323A (ja) * 2006-04-28 2009-10-01 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク オリゴヌクレオチド誘導体を合成する方法
US7674924B2 (en) * 2006-05-22 2010-03-09 Third Wave Technologies, Inc. Compositions, probes, and conjugates and uses thereof
EP2054514A4 (en) * 2006-08-04 2009-11-04 Univ Georgia State Res Found ENZYME SENSORS, METHODS OF PREPARATION AND USE OF SUCH SENSORS, AND METHODS OF DETECTING PROTEASE ACTIVITY
US8410247B2 (en) 2008-08-22 2013-04-02 Wisconsin Alumni Research Foundation Water-soluble phosphinothiol reagents
FI20095302A0 (fi) * 2009-03-24 2009-03-24 Arctic Partners Oy Ab Luminesenssimääritysmenetelmä
WO2011006786A1 (de) * 2009-07-13 2011-01-20 Siemens Aktiengesellschaft Verfahren zur plausibilitätsprüfung von digitalen messsignalen
GB201001088D0 (en) * 2010-01-23 2010-03-10 Trillion Genomics Ltd Detection
US20130323729A1 (en) 2010-10-29 2013-12-05 Olink Ab Proximity Ligation Technology for Western Blot Applications
CN105358984B (zh) 2013-03-15 2020-02-18 普罗格诺西斯生物科学公司 用于检测肽/mhc/tcr结合的方法
CA2950117C (en) 2013-06-04 2023-02-14 Tribiotica Llc Methods and compositions for templated assembly of nucleic acid specific heterocompounds
WO2015122835A1 (en) 2014-02-13 2015-08-20 Ge Healthcare Bio-Sciences Ab Method for protein analysis
CN107208313B (zh) 2014-12-02 2022-01-07 特里比奥迪卡有限责任公司 用于治疗诊断应用的方法和试剂盒
US10687542B2 (en) 2015-09-18 2020-06-23 Agrivida, Inc. Engineered phytases and methods of using the same

Also Published As

Publication number Publication date
CN105358691A (zh) 2016-02-24
US10603385B2 (en) 2020-03-31
SG11201509882WA (en) 2016-01-28
US20210023227A1 (en) 2021-01-28
EP3004351B1 (en) 2018-08-08
CA2950117C (en) 2023-02-14
AU2014275010B2 (en) 2020-10-29
WO2014197547A1 (en) 2014-12-11
JP6710157B2 (ja) 2020-06-17
US20160106854A1 (en) 2016-04-21
AU2020256386A1 (en) 2020-11-12
CA2950117A1 (en) 2014-12-11
AU2014275010A1 (en) 2015-12-17
AU2020256386B2 (en) 2023-07-27
HK1222201A1 (zh) 2017-06-23
IL242797B (en) 2021-12-01
SG10201710033PA (en) 2018-01-30
ZA201600024B (en) 2019-04-24
EP3004351A4 (en) 2016-12-21
JP2016521714A (ja) 2016-07-25
NZ714546A (en) 2021-10-29
EP3004351A1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
MX2015016371A (es) Métodos y composiciones para ensamblaje templado de heterocompuestos específicos de acido nucleico.
BR112016012883A2 (pt) Métodos e composições para aprimorar o rendimento de milho
MX2017007538A (es) Sintesis de ácido nucleíco de volúmen pequeño, alta eficiencia.
SG10201809312QA (en) Nucleic acid synthesis techniques
WO2014186585A3 (en) Methods and compositions for treatment of a genetic condition
MX2016007541A (es) Moléculas modificadas de ácido nucleico y usos de las mismas.
WO2015017527A3 (en) Methods for the production of long length clonal sequence verified nucleic acid constructs
CO7141403A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
BR112015023398A8 (pt) Métodos para amplificar ácidos nucléicos
MX2013001845A (es) Polipetidos que enlazan miostatina, composiciones y metodos.
EA201590868A1 (ru) Противовирусные соединения
TR201911139T4 (tr) Sitotoksik ve anti-mitotik bileşikler ve bunları kullanmanın yöntemleri.
PH12017500370A1 (en) Compound targeting il-23a and tnf-alpha and uses thereof
WO2015089492A3 (en) Dna antibody constructs and method of using same
MX2012014904A (es) Metodos de tratamiento utilizando inhibidores de tlr7 y/o tlr9.
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
WO2014153188A3 (en) High efficiency, small volume nucleic acid synthesis
MX2015013447A (es) Polipeptidos que tienen actividad de la fosfolipasa a y polinucleotidos que los codifican.
EP3321360A3 (en) Alpha-amylase variants and polynucleotides encoding same
MX2017009542A (es) Compuestos quimericos ramificados y lineales, polinucleotidos, usos y metodos para preparacion de los mismos.
EP3404032A3 (en) Process for making benzoxazepin compounds
PH12018500151A1 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
WO2014210416A8 (en) Helicase suppression of non-template amplification
MX2016006602A (es) Amplificacion de acidos nucleicos.
EA201491463A1 (ru) Способ получения соединения по новой реакции присоединения михаэля с применением воды или различных кислот в качестве добавки